The clinical characterization of the adult patient with bipolar disorder aimed at personalization of management

Abstract

Bipolar disorder is heterogeneous in phenomenology, illness trajectory, and response to treatment. Despite evidence for the efficacy of multimodal ity interventions, the majority of persons affected by this disorder do not achieve and sustain full syndromal recovery. It is eagerly anticipated that combining datasets across various information sources (e.g., hierarchical "multiomic" measures, electronic health records), analyzed using ad vanced computational methods (e.g., machine learning), will inform future diagnosis and treatment selection. In the interim, identifying clinically meaningful subgroups of persons with the disorder having differential response to specific treatments at pointofcare is an empirical priority. This paper endeavours to synthesize salient domains in the clinical characterization of the adult patient with bipolar disorder, with the overarching aim to improve health outcomes by informing patient management and treatment considerations. Extant data indicate that characterizing select domains in bipolar disorder provides actionable information and guides shared decision making. For example, it is robustly established that the presence of mixed features -especially during depressive episodes -and of physical and psychiatric comorbidities informs illness trajectory, response to treatment, and suicide risk. In addition, early environmental exposures (e.g., sexual and physical abuse, emotional neglect) are highly associated with more complicated illness presentations, inviting the need for developmentallyoriented and integrated treatment approaches. There have been significant advances in validating subtypes of bipolar disorder (e.g., bipolar I vs. II disorder), particularly in regard to pharmacological interventions. As with other severe mental disorders, social functioning, interpersonal/family relationships and internalized stigma are domains highly relevant to relapse risk, health outcomes, and quality of life. The elevated standardized mortality ratio for completed suicide and suicidal behaviour in bipolar disorder invites the need for characterization of this domain in all patients. The framework of this paper is to describe all the above salient domains, provid ing a synthesis of extant literature and recommendations for decision support tools and clinical metrics that can be implemented at pointofcare.

Long-acting injectable antipsychotics for the treatment of bipolar disorder: evidence from mirror-image studies

“…Bipolar disorder (BD), a chronic clinical condition characterized by recurrent mood oscillations and instability, 1 , 2 affects about 1–2% of the general population. 3 It is associated with poor quality of life, 4 co-occurring addictive behaviors 5 and physical comorbidities, 6 and high mortality rates.…”

Lithium use in childhood and adolescence, peripartum, and old age: an umbrella review

“…It has been approved for both adults and children and it is currently used from the age of 12 years until old age. However, clinical profiles of patients with mood disorders show a high level of heterogeneity during the course of life (Akiskal 1989 ; McIntyre et al 2022 ). While this variety of clinical presentation has been adequately addressed in the literature (Torre-Luque et al 2019 ; Sajatovic et al 2022 ; Meter et al 2011 ), lithium treatment response across the lifespan is less well-studied.…”

The future of psychopharmacology: a critical appraisal of ongoing phase 2/3 trials, and of some current trends aiming to de‐risk trial programmes of novel agents

“…The timely as well as effective and safe treatment of mental disorders is a key focus in medicine, due to the early onset of these disorders, and their severity, chronicity and major effects on multiple biopsychosocial aspects of human life 1‐4 . Clinicians, patients, family members and the society at large have substantial interest in the availability of new treatment options that have greater, broader or more specific efficacy and similar or enhanced tolerability compared to already available agents, ideally also involving new mechanisms of action that may help personalization of treatment 5‐7 .…”